Israel’s Brain-Drain Debate Is Asking the Wrong Question

Israel has good reason to worry about brain drain.

Highly educated and highly skilled Israelis have opportunities to build their careers abroad, and for a small country whose economic strength depends heavily on knowledge, innovation and human capital, that matters.

But the debate often focuses on the wrong measure.

The most important question is not simply how many talented people leave Israel. It is what capabilities leave with them, how difficult those capabilities are to replace and whether Israel possesses enough of them in the first place.

Not every departure has the same strategic consequence.

Israel’s universities produce exceptional talent, but no small economy can offer every highly trained person every possible career path. Some Israelis who spend years abroad acquire experience, expertise and professional networks that may ultimately benefit Israel. Some return. Others remain overseas while continuing to work with Israeli researchers, companies and investors.

International mobility is therefore not automatically a national loss.

The more serious problem is when Israel loses expertise that is already scarce, difficult to replace and important to industries the country wants to build.

There is also another possibility that receives less attention: sometimes the capability is insufficient before anyone leaves.

Biomedical innovation offers a useful example.

Israel has outstanding scientific research, strong universities and hospitals and an impressive ability to create biotechnology and medical technology startups. But scientific excellence and company formation are only the beginning of building a globally competitive biomedical industry.

Taking a medicine from discovery through clinical development, regulatory approval, manufacturing and commercialization requires specialized experience accumulated over many years. Much of that expertise comes from repeatedly developing products through the full process, learning from both successes and failures.

Israel has deep scientific and entrepreneurial talent. It has less depth in some of the capabilities required further along the development path.

That distinction matters.

If an experienced professional with rare expertise leaves Israel, the impact cannot be understood simply by adding another person to a brain-drain statistic. The more relevant question is how many people with comparable experience remain, how essential that expertise is and how easily it can be rebuilt.

And if an important capability is not present in sufficient depth to begin with, preventing people from leaving will not solve the problem. Israel must deliberately develop that expertise domestically or attract experienced people who already possess it.

This suggests a different approach to the brain-drain debate.

Instead of focusing primarily on the number of educated Israelis living abroad, policymakers should identify the capabilities Israel will need to support the industries it wants to build over the next decade. Which areas already have sufficient depth? Which depend on relatively small numbers of experienced people? Which are vulnerable to departures? And which capabilities remain underdeveloped altogether?

That kind of assessment could inform education, immigration, research funding, industrial policy and incentives for experienced professionals to return or relocate to Israel.

The objective should not be to keep every talented Israeli inside the country. That is neither realistic nor necessarily desirable in a global economy.

The objective should be to ensure that Israel has enough of the right expertise to develop, scale and sustain the industries on which its future prosperity will depend.

Brain drain is therefore not only a question of how many people leave.

The more consequential question is whether Israel still has the capabilities it needs after they do. 

Professor David Adler is Chief Scientific & Medical Officer of the PATHORA Institute of Pathology & Tissue Medicine. He is a senior pharmaceutical leader in oncology drug development and translational medicine with over 15 years of experience, including a decade in senior leadership at Bayer AG’s Global Oncology Clinical Development organization. He holds academic appointments at the Hebrew University of Jerusalem, Ben-Gurion University of the Negev, and the University of Bonn.